Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Okoro, Danielle R ^a   Arva, Nicoleta ^a   Gao, Chong ^a   Polotskaia, Alla ^a   Puente, Cindy ^a   Rosso, Melissa ^a   Bargonetti, Jill ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN ANTIBODY; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESEARCH; CANCER TISSUE; CARCINOGENESIS; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CYTOPLASM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR WEIGHT; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885405349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077643     Document Type: Article

References (73)

1. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799. PubMed: 8306343.
2. Landers JE, Haines DS, Strauss JF 3rd, George DL, (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750. PubMed: 8058341.
3. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J, (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2: 912-917. doi:10.1038/nm0896-912. PubMed: 8705862.
4. Haines DS, Landers JE, Engle LJ, George DL, (1994) Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 14: 1171-1178. PubMed: 8289798.
5. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245. doi:10.1016/0092-8674(92)90644-R. PubMed: 1535557.
6. Wu X, Bayle JH, Olson D, Levine AJ, (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132. doi:10.1101/gad.7.7a.1126. PubMed: 8319905.
7. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. doi:10.1038/387296a0. PubMed: 9153395.
8. Honda R, Tanaka H, Yasuda H, (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27. doi:10.1016/S0014-5793(97)01480-4. PubMed: 9450543.
9. Kubbutat MH, Jones SN, Vousden KH, (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303. doi:10.1038/387299a0. PubMed: 9153396.
10. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH, (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18: 5690-5698. PubMed: 9742086.
11. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860. doi:10.1038/362857a0. PubMed: 8479525.
12. Thut CJ, Goodrich JA, Tjian R, (1997) Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11: 1974-1986. doi:10.1101/gad.11.15.1974. PubMed: 9271120.
13. White DE, Talbott KE, Arva NC, Bargonetti J, (2006) Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res 66: 3463-3470. doi:10.1158/0008-5472.CAN-05-1381. PubMed: 16585169.
14. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, et al. (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776-26787. doi:10.1074/jbc.M505203200. PubMed: 15908423.
15. Loughran O, La Thangue NB, (2000) Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 20: 2186-2197. doi:10.1128/MCB.20.6.2186-2197.2000. PubMed: 10688665.
16. Martin K, Trouche D, Hagemeier C, Sørensen TS, La Thangue NB, et al. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694. doi:10.1038/375691a0. PubMed: 7791903.
17. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, et al. (2005) Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 280: 18771-18781. doi:10.1074/jbc.M413387200. PubMed: 15734743.
18. Bouska A, Eischen CM, (2009) Mdm2 affects genome stability independent of p53. Cancer Res 69: 1697-1701. doi:10.1158/0008-5472.CAN-08-3732. PubMed: 19244108.
19. Bouska A, Lushnikova T, Plaza S, Eischen CM, (2008) Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 28: 4862-4874. doi:10.1128/MCB.01584-07. PubMed: 18541670.
20. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res 66: 5104-5110. doi:10.1158/0008-5472.CAN-06-0180. PubMed: 16707433.
21. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. doi:10.1016/j.cell.2004.11.022. PubMed: 15550242.
22. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, et al. (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98: 911-919. doi:10.1093/jnci/djj245. PubMed: 16818855.
23. Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, et al. (2010) A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18: 220-230. doi:10.1016/j.ccr.2010.07.010. PubMed: 20832750.
24. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, et al. (1998) Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 58: 609-613. PubMed: 9485008.
25. Bartel F, Taylor AC, Taubert H, Harris LC, (2001) Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 12: 451-457. PubMed: 11939408.
26. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, et al. (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61: 3212-3219. PubMed: 11306511.
27. Liang H, Atkins H, Abdel-Fattah R, Jones SN, Lunec J, (2004) Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 338: 217-223. doi:10.1016/j.gene.2004.05.015. PubMed: 15315825.
28. Sánchez-Aguilera A, García JF, Sánchez-Beato M, Piris MA, (2006) Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene 25: 2565-2574. doi:10.1038/sj.onc.1209282. PubMed: 16331255.
29. Bartel F, Taubert H, Harris LC, (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2: 9-15. doi:10.1016/S1535-6108(02)00091-0. PubMed: 12150820.
30. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74. doi:10.1038/nature11247. PubMed: 22955616.
31. Okoro DE, Rosso M, Bargonetti J, (2012) Splicing Up Mdm2 for Cancer Proteome Diversity. Genes and Cancer.
32. Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, et al. (2008) Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis 18: S2-1-8. PubMed: 18646312.
33. Volk EL, Schuster K, Nemeth KM, Fan L, Harris LC, (2009) MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. Dis Models Mechanisms 2: 47-55. doi:10.1242/dmm.000992. PubMed: 19132120.
34. Volk EL, Fan L, Schuster K, Rehg JE, Harris LC, (2009) The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis. Mol Cancer Res MCR 7: 863-869. doi:10.1158/1541-7786.MCR-08-0418. PubMed: 19491200.
35. Steinman HA, Burstein E, Lengner C, Gosselin J, Pihan G, et al. (2004) An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis. J Biol Chem 279: 4877-4886. PubMed: 14612455.
36. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J, (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res BCR 13: R3. doi:10.1186/bcr2955. PubMed: 21223569.
37. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 103: 1888-1893. doi:10.1073/pnas.0507493103. PubMed: 16443686.
38. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G, (2006) Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 66: 9502-9508. doi:10.1158/0008-5472.CAN-05-4271. PubMed: 17018606.
39. Jeyaraj S, O'Brien DM, Chandler DS, (2009) MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Front Biosci J Virtual Libr 14: 2647-2656. PubMed: 19273224.
40. Dias CS, Liu Y, Yau A, Westrick L, Evans SC, (2006) Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res 66: 9467-9473. doi:10.1158/0008-5472.CAN-05-3013. PubMed: 17018602.
41. Anderson JJ, Challen C, Atkins H, Suaeyun R, Crosier S, et al. (2007) MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14. Int J Oncol 31: 545-555. PubMed: 17671681.
42. Chen J, Marechal V, Levine AJ, (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114. PubMed: 7686617.
43. Schuster K, Fan L, Harris LC, (2007) MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol Cancer Res MCR 5: 403-412. doi:10.1158/1541-7786.MCR-06-0146. PubMed: 17426254.
44. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, et al. (2003) Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 63: 5703-5706. PubMed: 14522887.
45. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J, (2012) Correction: A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res BCR 14: 302. doi:10.1186/bcr3130.
46. Adachi T, Oda Y, Sakamoto A, Saito T, Tamiya S, et al. (2001) Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int J Surg Pathol 9: 99-109. doi:10.1177/106689690100900203. PubMed: 11484509.
47. Tamborini E, Della Torre G, Lavarino C, Azzarelli A, Carpinelli P, et al. (2001) Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer J Int Cancer 92: 790-796. doi:10.1002/ijc.1271. PubMed: 11351297.
48. Schneider-Stock R, Walter H, Radig K, Rys J, Bosse A, et al. (1998) MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol 124: 532-540. doi:10.1007/s004320050211. PubMed: 9829856.
49. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, et al. (1995) MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer J Int Cancer 64: 342-346. doi:10.1002/ijc.2910640511. PubMed: 7591308.
50. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, et al. (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20: 4041-4049. doi:10.1038/sj.onc.1204533. PubMed: 11494132.
51. Sandberg AA, (2004) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 155: 1-24. doi:10.1016/S0165-4608(04)00463-7. PubMed: 15527898.
52. Takagi M, Absalon MJ, McLure KG, Kastan MB, (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49-63. doi:10.1016/j.cell.2005.07.034. PubMed: 16213212.
53. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, et al. (2008) P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 10: 1098-1105. doi:10.1038/ncb1770. PubMed: 19160491.
54. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fåhraeus R, et al. (2009) The p53 mRNA-Mdm2 interaction. Cell Cycle 8: 31-34. doi:10.4161/cc.8.1.7326. PubMed: 19106616.
55. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M, (2008) Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell 32: 180-189. doi:10.1016/j.molcel.2008.08.031. PubMed: 18951086.
56. Clancy S, (2008) RNA functions. Nature. Education 1.
57. Serganov A, Patel DJ, (2007) Ribozymes, riboswitches and beyond: regulation of gene expression without proteins. Nat Rev Genet 8: 776-790. doi:10.1038/nrg2172. PubMed: 17846637.
58. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, et al. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23: 4929-4938. doi:10.1128/MCB.23.14.4929-4938.2003. PubMed: 12832478.
59. Ma J, Martin JD, Zhang H, Auger KR, Ho TF, et al. (2006) A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45: 9238-9245. doi:10.1021/bi060661u. PubMed: 16866370.
60. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, et al. (2006) The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A 103: 1227-1232. doi:10.1073/pnas.0510343103. PubMed: 16432196.
61. Freedman DA, Levine AJ, (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18: 7288-7293. PubMed: 9819415.
62. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, et al. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2: 405-415. doi:10.1016/S1097-2765(00)80140-9. PubMed: 9809062.
63. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, et al. (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989. doi:10.1038/nsmb.1872. PubMed: 20639885.
64. Deb SP, (2003) Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res MCR 1: 1009-1016. PubMed: 14707284.
65. Nevins JR, (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703. doi:10.1093/hmg/10.7.699. PubMed: 11257102.
66. Trinh E, Boutillier AL, Loeffler JP, (2001) Regulation of the retinoblastoma-dependent Mdm2 and E2F-1 signaling pathways during neuronal apoptosis. Mol Cell Neurosci 17: 342-353. doi:10.1006/mcne.2000.0928. PubMed: 11178871.
67. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A, (2010) The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol 20: 258-266. doi:10.1016/j.semradonc.2010.05.007. PubMed: 20832018.
68. Datto MB, Yu Y, Wang XF, (1995) Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270: 28623-28628. doi:10.1074/jbc.270.48.28623. PubMed: 7499379.
69. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722. PubMed: 2253215.
70. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW, (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311. PubMed: 1933891.
71. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, et al. (1996) Formation of p27-CDK complexes during the human mitotic cell cycle. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 7: 135-146. PubMed: 8822197.
72. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C, (1993) A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7: 2565-2574. doi:10.1101/gad.7.12b.2565. PubMed: 8276239.
73. Mozzherin DJ, Fisher PA, (1996) Human DNA polymerase epsilon: enzymologic mechanism and gap-filling synthesis. Biochemistry 35: 3572-3577. doi:10.1021/bi952142p. PubMed: 8639508.